OncoGenex Pharmaceuticals Inc

1522 217th Pl SE , Bothell, WA 98021

Public
Healthcare & Pharmaceuticals - Others
around $2.5 - 5M
around 20 - 50
(425) 686-1500
(302) 636-5454


OncoGenex Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company's segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company's product candidates include Custirsen, Apatorsen and OGX-225. The Company is focused on targeting these particular proteins to disable the tumor cell's adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies. Of these product candidates, Custirsen and Apatorsen are clinical-stage assets. Custirsen is being evaluated in two Phase III trials. Apatorsen is a product candidate designed to... (Source: SEC reports)


Competitor - 1/8
Which company is more competitive with OncoGenex Pharmaceuticals Inc?


9 Contacts at this company
Dave Porubek
Director, Project Management
David Porubek
Director, Project Management
Carol Bailey
Directory Regulatory Affairs
Cindy Jacobs
Exec VP, CMO
Patricia Stewart
Senior Medical Director
Daniel Cain
Director, Clinical Research
Connie Mui
Senior Manager, Clinical Data Management

Jan 5, 2017 20:44:46
BOTHELL, Wash. and VANCOUVER, British Columbia and MILL VALLEY, Calif., Jan. 5, 2017 /PRNewswire/ --OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) (\"OncoGenex\"), a publicly held oncology biopharmaceutical company, and Achieve [...]

Nov 10, 2016 20:42:37
BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 10, 2016 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its third quarter 2016 financial results.   Recent Events [...]

Nov 3, 2016 21:47:31
BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 3, 2016 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it will report its third quarter 2016 financial [...]

Get Started Today : Sign up in 20 seconds
Search with 20+ criteria.
Export results in seconds.
Bad emails?
No worry, we give two extras for every bad email.